Researchers discover new brain tumor subtypes that could identify a treatment for incurable brain cancer

Researchers discover new brain tumor subtypes that could identify a treatment for incurable brain cancer

pre- vs post-adjuvant anti-PD1 treatment in available tumor samples (N = 24). B. OS according to TMEHigh and not TMEHigh (TMEDown + TMEWith) subtypes who received adjuvant anti-PD1 therapy in the Zhao cohort (N = 15 patients). C. Relative boxplots indicating the proportion of TMEDown, TMEWith and TMEHigh patients before administration of anti-PD1 treatment (left) and after anti-PD1 treatment (right) in available tumor and blood samples. D. Grouping of the partition around the medoids (PAM) of the PVSRIPO cohort19Desjardins A. Gromeier M. Herndon JE Beaubier N. Bolognesi DP Friedman AH et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus.New England Journal of Medicine. July 12, 2018; 379: 150-161CrossrefPubMedScopus (0)Google Scholar with available RNA-seq data (N=12), based on the cellular composition of TME described by GBM-MCP-counter scores reveal 3 subtypes; TMEdownTME with and TME high. E. OS according to TMEDown and TMEWith and TMEHigh subtypes who received treatment with PVSRIPO in the PVSRIPO cohort19Desjardins A. Gromeier M. Herndon JE Beaubier N. Bolognesi DP Friedman AH et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus.New England Journal of Medicine. July 12, 2018; 379: 150-161CrossrefPubMedScopus (0)Google Scholar. Statistical test: Wilcoxon signed rank test. Kaplan Meier analysis; P value of the logarithmic test. *P<0.05 **P<0.01. Credit: Annals of Oncology (2022). DOI: 10.1016/j.annonc.2022.11.008″>

Researchers discover new brain tumour subtypes that may identify treatment for incurable brain cancer pre- vs post-adjuvant anti-PD1 treatment in available tumor samples (N = 24). B. OS according to TMEHigh and not TMEHigh (TMEDown + TMEWith) subtypes who received adjuvant anti-PD1 therapy in the Zhao cohort (N = 15 patients). C. Relative boxplots indicating the proportion of TMEDown, TMEWith and TMEHigh patients before administration of anti-PD1 treatment (left) and after anti-PD1 treatment (right) in available tumor and blood samples. D. Grouping of the partition around the medoids (PAM) of the PVSRIPO cohort19Desjardins A. Gromeier M. Herndon JE Beaubier N. Bolognesi DP Friedman AH et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus.New England Journal of Medicine. July 12, 2018; 379: 150-161CrossrefPubMedScopus (0)Google Scholar with available RNA-seq data (N=12), based on the cellular composition of TME described by GBM-MCP-counter scores reveal 3 subtypes; TMEdownTME with and TME high. E. OS according to TMEDown and TMEWith and TMEHigh subtypes who received treatment with PVSRIPO in the PVSRIPO cohort19Desjardins A. Gromeier M. Herndon JE Beaubier N. Bolognesi DP Friedman AH et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus.New England Journal of Medicine. July 12, 2018; 379: 150-161CrossrefPubMedScopus (0)Google Scholar. Statistical test: Wilcoxon signed rank test. Kaplan Meier analysis; P value of the logarithmic test. *P<0.05 **P<0.01. Credit: Annals of Oncology (2022). DOI: 10.1016/j.annonc.2022.11.008″ width=”546″ height=”530″/>
Trend of improving OS and increasing response rate in TMEHigh patients on adjuvant therapy with pembrolizumab or PVSRIPO. A. Composition of TME in the Zhao dataset18Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. NatMed. 2019 Mar 11;25(3):462–469. Available at: http://www.nature.com/articles/s41591-019-0349-yGoogle Scholar